San Diego-based Accriva Diagnostics has raised about $15.5 million in equity, according to a regulatory filing. The fresh capital comes on the heels of last year’s round that brought in $55 million.
The company offers point-of-care tests for strokes and other cardiovascular conditions, including an anticoagulation monitoring system called Hemochron that measures a patient’s platelet reactivity to antiplatelet meds, a heelstick device for newborns and several others. One of its devices, the InRhythm, isn’t yet FDA approved – the rest are.
Previous Accriva’s investors include Warburg Pincus, Bay City Capital and Kleiner Perkins Caufield and Byers.
Accriva was formed in 2013 after a merger between ITC Nexus and Accumetrics.